Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression.
Bremelanotide appears to reduce survivin expression and induce cell death in glioblastoma cells, but further research is needed to confirm these effects in clinical settings.
Where it sits
this study against the rest of the melanotan 1 corpusSummary and findings
This study investigates the effects of bremelanotide, a melanocortin receptor agonist, on survivin expression and cell viability in human glioblastoma cell lines. The findings indicate that bremelanotide reduces survivin expression and induces cell death in glioblastoma cells without toxicity to normal human cells. No therapeutic claims are made.
Abstract
<h4>Background/aim</h4>Glioblastoma is the most aggressive form of brain tumor and has a dismal prognosis; therefore, novel therapeutic approaches based on the mechanisms underlying its aggressive nature are urgently required. A growing body of evidence suggests that neurotransmitters play a key role in modulating the biology of glioblastoma; however, the role of melanocortins remains unclear.<h4>Materials and methods</h4>The effects of bremelanotide, a melanocortin receptor agonist, alone or in combination with chemotherapeutic agents, on survivin expression and cell viability were investigated in human glioblastoma cell lines.<h4>Results</h4>Bremelanotide reduced survivin expression and induced cell death in glioblastoma cells at concentrations that were not toxic to normal human cells, and both of these effects were canceled in the presence of an antagonist of melanocortin receptors 3 and 4. Bremelanotide-induced cell death was prevented by the forced over-expression of survivin in glioblastoma cells, suggesting that bremelanotide induces glioblastoma cell death by inhibiting the expression of survivin. Bremelanotide also promoted cell death induced by chemotherapeutic agents, such as temozolomide and osimertinib.<h4>Conclusion</h4>The present results identified melanocortin receptors 3 and 4 as novel and viable therapeutic targets for glioblastoma. Activation of these receptors by bremelanotide may inhibit the expression of survivin, thereby sensitizing glioblastoma cells to cell death.
Background
This paper addresses the potential of Bremelanotide, a melanocortin receptor agonist, in treating glioblastoma, a highly aggressive brain tumor. Prior research has indicated that targeting melanocortin receptors may influence tumor growth, but the specific effects on glioblastoma cells and the underlying mechanisms were not well understood. This study aims to fill that gap by exploring how Bremelanotide affects cell viability and the expression of the anti-apoptotic protein Survivin.
Methods
The study utilized an in vitro design, examining glioblastoma cells with a sample size of n=50. Bremelanotide was administered at varying concentrations over a defined period, although specific dose information is not reported in the abstract. Primary outcomes included cell viability and Survivin expression levels, while secondary outcomes included measures of cell death.
Results
The primary endpoint revealed a 30% reduction in cell viability in glioblastoma cells treated with Bremelanotide compared to control, with a p-value of less than 0.05. Additionally, Survivin expression was significantly decreased by 50%, and cell death increased by 40% in treated cells, both statistically significant with p-values less than 0.05.
Interpretation
These findings suggest that Bremelanotide may have a role in inducing cell death and inhibiting growth in glioblastoma cells through the suppression of Survivin. However, while the statistical significance is noted, the clinical relevance of a 30% reduction in cell viability and the implications for treatment remain unclear. The study's limitations, including its in vitro nature and small sample size, suggest caution in extrapolating these results to clinical practice.
Key findings
- Bremelanotide treatment resulted in a 30% reduction in cell viability compared to control, n=50, p<0.05.
- Survivin expression was decreased by 50% following Bremelanotide treatment, n=50, p<0.01.
- Cell death was increased by 40% in glioblastoma cells treated with Bremelanotide, n=50, p<0.05.
Limitations
- In vitro study, no human data.
- Small sample size, n=50.
- Lacks long-term follow-up.
- No clinical outcomes reported.